# US 2020/0390905 A1 · Compositions and methods for treating non-age-associated hearing impairment in a human subject

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390905 A1
- Document ID: US20200390905A1
- Status: Published application
- Kind: A1
- Application number: 16/971,922
- Filed: 2019-02-22
- Published: 2020-12-17
- Earliest claimed: 2018-02-22
- Assignees: Akouos, Inc.
- Applicants: Akouos, Inc.
- Inventors: Emmanuel John Simons; Robert Ng; Ellen Reisinger; Hanan Al-Moyed; Sebastian Kügler
- Web page: https://patentgrep.com/patent/US20200390905A1

## CPC

- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- C12N 15/86: Viral vectors
- A01K 67/0276: Knock-out vertebrates
- A61K 9/0046: {Ear}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 9/5153: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/16: Otologicals
- C07K 14/435: from animals; from humans
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C12N 15/65: using markers (enzymes used as markers C12N15/52)
- A01K 2217/075: inducing loss of function, i.e. knock out
- A01K 2227/103: Ovine
- A01K 2227/105: Murine
- A01K 2267/0306: Animal model for genetic diseases
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2800/40: Systems of functionally co-operating vectors
- C12N 2830/48: regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
- C12N 2830/50: regulating RNA stability, not being an intron, e.g. poly A signal
- C12N 2840/44: being a specific part of the splice mechanism, e.g. donor, acceptor
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided herein are compositions that include at least two different nucleic acid vectors, where each of the at least two different vectors includes a coding sequence that encodes a different portion of an otoferlin protein, and the use of these compositions to treat hearing loss in a subject.

## Claims

### Claim 1

A composition comprising at least two different nucleic acid vectors, wherein:
each of the at least two different vectors comprises a coding sequence that encodes a different portion of an otoferlin protein, each of the encoded portions being at least 30 amino acid residues in length, wherein the amino acid sequence of each of the encoded portions may optionally partially overlap with the amino acid sequence of a different one of the encoded portions;
no single vector of the at least two different vectors encodes a full-length otoferlin protein;
at least one of the coding sequences comprises a nucleotide sequence spanning two neighboring exons of otoferlin genomic DNA, and lacks an intronic sequence between the two neighboring exons; and
when introduced into a mammalian cell the at least two different vectors undergo concatamerization or homologous recombination with each other, thereby forming a recombined nucleic acid that encodes a full-length otoferlin protein.

### Claim 2 (depends on 1)

The composition of claim 1, wherein each of the at least two different vectors is a plasmid, a transposon, a cosmid, an artificial chromosome, or a viral vector.

### Claim 3 (depends on 1)

The composition of claim 1, wherein each of the at least two different vectors is a human artificial chromosome (HAC), yeast artificial chromosome (YAC), bacterial artificial chromosome (BAC), or a P1-derived artificial chromosome (PAC).

### Claim 4 (depends on 1)

The composition of claim 1, wherein each of the at least two different vectors is a viral vector selected from an adeno-associated virus (AAV) vector, an adenovirus vector, a lentivirus vector, or a retrovirus vector.

### Claim 5 (depends on 1)

The composition of claim 1, wherein each of the at least two different vectors is an AAV vector.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The composition of any one of claims 1-5, wherein the amino acid sequence of one of the encoded portions overlaps with the amino acid sequence of a different one of the encoded portions.

### Claim 7 (depends on 6)

The composition of claim 6, wherein the amino acid sequence of each of the encoded portions partially overlaps with the amino acid sequence of a different encoded portion.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the overlapping amino acid sequence is between about 30 amino acid residues to about 1000 amino acid residues in length.

### Claim 9 (depends on 1, 2, 3, 4, 5)

The composition of any one of claims 1-5, wherein the vectors include two different vectors, each of which comprises a different segment of an intron, wherein the intron comprises the nucleotide sequence of an intron that is present in otoferlin genomic DNA, and wherein the two different segments overlap in sequence by at least 100 nucleotides.

### Claim 10 (depends on 9)

The composition of claim 9, wherein the two different segments overlap in sequence by about 100 nucleotides to about 800 nucleotides.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The composition of any one of claims 1-10, wherein the nucleotide sequence of each of the at least two different vectors is between about 500 nucleotides to about 10,000 nucleotides in length.

### Claim 12 (depends on 11)

The composition of claim 11, wherein the nucleotide sequence of each of the at least two different vectors is between 500 nucleotides to 5,000 nucleotides in length.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The composition of any one of claims 1-12, wherein the number of different vectors in the composition is two.

### Claim 14 (depends on 13)

The composition of claim 13, wherein a first of the two different vectors comprises a coding sequence that encodes an N-terminal portion of the otoferlin protein.

### Claim 15 (depends on 14)

The composition of claim 14, wherein the N-terminal portion of the otoferlin protein is between 30 amino acids to 1600 amino acids in length.

### Claim 16 (depends on 15)

The composition of claim 15, wherein the N-terminal portion of the otoferlin protein is between 200 amino acids to 1500 amino acids in length.

### Claim 17 (depends on 14, 15, 16)

The composition of any one of claims 14-16, wherein the first vector further comprises one or both of a promoter and a Kozak sequence.

### Claim 18 (depends on 17)

The composition of claim 17, wherein the first vector comprises a promoter that is an inducible promoter, a constitutive promoter, or a tissue-specific promoter.

### Claim 19 (depends on 14, 15, 16, 17, 18)

The composition of any one of claims 14-18, wherein the first vector further comprises a coding sequence encoding a destabilization domain, wherein the destabilization domain is 3′ to the coding sequence that encodes the N-terminal portion of the otoferlin protein.

### Claim 20 (depends on 19)

The composition of claim 19, wherein the coding sequence that encodes the N-terminal portion of the otoferlin protein comprises exons 1-21 of isoform 5 of the human otoferlin gene.

### Claim 21 (depends on 14, 15, 16, 17, 18, 19, 20)

The composition of any one of claims 14-20, wherein the second of the two different vectors comprises a coding sequence that encodes a C-terminal portion of the otoferlin protein.

### Claim 22 (depends on 21)

The composition of claim 21, wherein the C-terminal portion of the otoferlin protein is between 30 amino acids to 1600 amino acids in length.

### Claim 23 (depends on 22)

The composition of claim 22, wherein the C-terminal portion of the otoferlin protein is between 200 amino acids to 1500 amino acids in length.

### Claim 24 (depends on 21, 22, 23)

The composition of any one of claims 21-23, wherein the second vector further comprises a poly(dA) sequence.

### Claim 25 (depends on 21)

The composition of claim 21, wherein the coding sequence that encodes the C-terminal portion of the otoferlin protein comprises exons 22-47 of isoform 5 of the human otoferlin gene.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The composition of any one of claims 1-25, further comprising a pharmaceutically acceptable excipient.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

A kit comprising a composition of any one of claims 1-26.

### Claim 28 (depends on 27)

A kit of claim 27, further comprising a pre-loaded syringe comprising the composition.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

A method comprising:
introducing into a cochlea of a mammal a therapeutically effective amount of the composition of any one of claims 1-26.

### Claim 30 (depends on 29)

The method of claim 29, wherein the mammal is a human.

### Claim 31 (depends on 29, 30)

The method of claim 29 or 30, wherein the mammal has been previously identified as having a defective otoferlin gene.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

A method of increasing expression of a full-length otoferlin protein in a mammalian cell, the method comprising introducing the composition of any one of claims 1-26 into the mammalian cell.

### Claim 33 (depends on 32)

The method of claim 32, wherein the mammalian cell is an inner hair cell.

### Claim 34 (depends on 32, 33)

The method of claim 32 or 33, wherein the mammalian cell is a human cell.

### Claim 35 (depends on 32, 33, 34)

The method of any one of claims 32-34, wherein the mammalian cell has previously been determined to have a defective otoferlin gene.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

A method of increasing expression of a full-length otoferlin protein in an inner hair cell in a cochlea of a mammal, the method comprising:
introducing into the cochlea of the mammal a therapeutically effective amount of the composition of any one of claims 1-26.

### Claim 37 (depends on 36)

The method of claim 36, wherein the mammal has been previously identified as having a defective otoferlin gene.

### Claim 38 (depends on 36, 37)

The method of claim 36 or 37, wherein the mammal is a human.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

A method of treating non-symptomatic sensorineural hearing loss in a subject identified as having a defective otoferlin gene, the method comprising:
administering a therapeutically effective amount of a composition of any one of claims 1-26 into the cochlea of the subject.

### Claim 40 (depends on 39)

The method of claim 39, wherein the subject is a human.

### Claim 41 (depends on 39, 40)

The method of claim 39 or 40, further comprising, prior to the administering step, determining that the subject has a defective otoferlin gene.

### Claim 42

A composition comprising two different nucleic acid vectors, wherein:
a first nucleic acid vector of the two different nucleic acid vectors comprises a promoter, a first coding sequence that encodes an N-terminal portion of an otoferlin protein positioned 3′ of the promoter, and a splicing donor signal sequence positioned at the 3′ end of the first coding sequence; and
a second nucleic acid vector of the two different nucleic acid vectors comprises a splicing acceptor signal sequence, a second coding sequence that encodes a C-terminal portion of an otoferlin protein positioned at the 3′ end of the splicing acceptor signal sequence, and a polyadenylation sequence at the 3′ end of the second coding sequence;
wherein each of the encoded portions is at least 30 amino acid residues in length, wherein the amino acid sequences of the encoded portions do not overlap, wherein no single vector of the two different vectors encodes a full-length otoferlin protein, and, when the coding sequences are transcribed in a mammalian cell, to produce RNA transcripts, splicing occurs between the splicing donor signal sequence on one transcript and the splicing acceptor signal sequence on the other transcript, thereby forming a recombined RNA molecule that encodes a full-length otoferlin protein.

### Claim 43 (depends on 42)

The composition of claim 42, wherein the coding sequence of at least one of the vectors comprises a nucleotide sequence spanning two neighboring exons of otoferlin genomic DNA, and lacks an intronic sequence between the two neighboring exons.

### Claim 44

A composition comprising:
a first nucleic acid vector comprising a promoter, a first coding sequence that encodes an N-terminal portion of an otoferlin protein positioned 3′ of the promoter, a splicing donor signal sequence positioned at the 3′ end of the first coding sequence, and a first detectable marker gene positioned 3′ of the splicing donor signal sequence; and
a second nucleic acid vector, different from the first nucleic acid vector, comprising a second detectable marker gene, a splicing acceptor signal sequence positioned 3′ of the second detectable marker gene, a second coding sequence that encodes a C-terminal portion of an otoferlin protein positioned at the 3′ end of the splicing acceptor signal sequence, and a polyadenylation sequence positioned at the 3′ end of the second coding sequence;
wherein each of the encoded portions is at least 30 amino acid residues in length, wherein the respective amino acid sequences of the encoded portions do not overlap with each other, wherein no single vector of the two different vectors encodes a full-length otoferlin protein, and, when the coding sequences are transcribed in a mammalian cell to produce RNA transcripts, splicing occurs between the splicing donor signal on one transcript and the splicing acceptor signal on the other transcript, thereby forming a recombined RNA molecule that encodes a full-length otoferlin protein.

### Claim 45 (depends on 44)

The composition of claim 44, wherein the coding sequence of at least one of the vectors comprises a nucleotide sequence spanning two neighboring exons of otoferlin genomic DNA, and lacks an intronic sequence between the two neighboring exons.

### Claim 46 (depends on 44)

The composition of claim 44, wherein the first or second detectable marker gene encodes alkaline phosphatase.

### Claim 47 (depends on 44, 46)

The composition of claim 44 or 46, wherein the first and second detectable marker genes are the same.

### Claim 48

A composition comprising:
a first nucleic acid vector comprising a promoter, a first coding sequence that encodes an N-terminal portion of an otoferlin protein positioned 3′ to the promoter, a splicing donor signal sequence positioned at the 3′ end of the first coding sequence, and a F1 phage recombinogenic region positioned 3′ to the splicing donor signal sequence; and
a second nucleic acid vector, different from the first nucleic acid vector, comprising a second F1 phage recombinogenic region, a splicing acceptor signal sequence positioned 3′ of the second F1 phage recombinogenic region, a second coding sequence that encodes a C-terminal portion of an otoferlin protein positioned at the 3′ end of the splicing acceptor signal sequence, and a polyadenylation sequence positioned at the 3′ end of the second coding sequence;
wherein each of the encoded portions is at least 30 amino acid residues in length, wherein the respective amino acid sequences of the encoded portions do not overlap with each other, wherein no single vector of the two different vectors encodes a full-length otoferlin protein, and, when the coding sequences are transcribed in a mammalian cell to produce RNA transcripts, splicing occurs between the splicing donor signal one transcript and the splicing acceptor signal on the other transcript, thereby forming a recombined RNA molecule that encodes a full-length otoferlin protein.

### Claim 49 (depends on 48)

The composition of claim 48, wherein the coding sequence of at least one of the vectors comprises a nucleotide sequence spanning two neighboring exons of otoferlin genomic DNA, and lacks an intronic sequence between the two neighboring exons.

### Claim 50 (depends on 42, 43, 44, 45, 46, 47, 48, 49)

A kit comprising a composition of any one of claims 42-49.

### Claim 51 (depends on 50)

A kit of claim 50, wherein the composition is pre-loaded in a syringe.

### Claim 52 (depends on 42, 43, 44, 45, 46, 47, 48, 49)

A method comprising introducing into a cochlea of a mammal a therapeutically effective amount of the composition of any one of claims 42-49.

### Claim 53 (depends on 52)

The method of claim 52, wherein the mammal is a human.

### Claim 54 (depends on 52, 53)

The method of claim 52 or 53, wherein the mammal has been previously identified as having a defective otoferlin gene.

### Claim 55 (depends on 42, 43, 44, 45, 46, 47, 48, 49)

A method of increasing expression of a full-length otoferlin protein in a mammalian cell, the method comprising introducing the composition of any one of claims 42-49 into the mammalian cell.

### Claim 56 (depends on 55)

The method of claim 55, wherein the mammalian cell is a cochlear inner hair cell.

### Claim 57 (depends on 55, 56)

The method of claim 55 or 56, wherein the mammalian cell is a human cell.

### Claim 58 (depends on 55, 56, 57)

The method of any one of claims 55-57, wherein the mammalian cell has previously been determined to have a defective otoferlin gene.

### Claim 59 (depends on 39, 40, 41, 42, 43, 44, 45, 46)

A method of increasing expression of a full-length otoferlin protein in an inner hair cell in a cochlea of a mammal, the method comprising introducing into the cochlea a therapeutically effective amount of the composition of any one of claims 39-46.

### Claim 60 (depends on 59)

The method of claim 59, wherein the mammal has been previously identified as having a defective otoferlin gene.

### Claim 61 (depends on 59, 60)

The method of claim 59 or 60, wherein the mammal is a human.

### Claim 62 (depends on 42, 43, 44, 45, 46, 47, 48, 49)

A method of treating non-symptomatic sensorineural hearing loss in a subject identified as having a defective otoferlin gene, the method comprising administering a therapeutically effective amount of a composition of any one of claims 42-49 into a cochlea of the subject.

### Claim 63 (depends on 62)

The method of claim 62, wherein the subject is a human.

### Claim 64 (depends on 62, 63)

The method of claim 62 or 63, further comprising, prior to the administering step, determining that the subject has a defective otoferlin gene.

### Claim 65 (depends on 13)

The composition of claim 13, wherein the one of the two vectors comprises SEQ ID NO: 39 and the second of the two vectors comprises SEQ ID NO: 40.

### Claim 66 (depends on 13)

The composition of claim 13, wherein the one of the two vectors comprises SEQ ID NO: 41 and the second of the two vectors comprises SEQ ID NO: 42.

### Claim 67 (depends on 13)

The composition of claim 13, wherein one of the two vectors comprises SEQ ID NO:84 and the second of the two vectors comprises SEQ ID NO: 85.

### Claim 68 (depends on 1)

The composition of claim 1, wherein one of the at least two different vectors comprises a sequence encoding a NTF3 protein.

### Claim 69 (depends on 68)

The composition of claim 68, wherein the sequence encoding a NTF3 protein is at least 90% identical to SEQ ID NO: 78.
